Maddi Hebebrand, MC, Associate Editor

Oruka Therapeutics reveals promising interim results for ORKA-002 and launches the EVERLAST-B trial for ORKA-001, targeting chronic skin diseases.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Discover how vitamin D receptor signaling influences hair follicle health and alopecia, revealing new therapeutic possibilities for hair loss management.

Navigator Medicines advances NAV-240 and NAV-242, targeting dual inflammation pathways for hidradenitis suppurativa in upcoming clinical trials.

Research reveals that structural changes in neoantigens enhance tumor rejection, offering new insights for personalized cancer immunotherapies.

MoonLake Immunotherapeutics shares promising updates on sonelokimab's efficacy for hidradenitis suppurativa.

Johnson & Johnson reveals JNJ-95475939's early termination due to insufficient efficacy in treating moderate-to-severe atopic dermatitis.

Verrica Pharmaceuticals initiates phase 3 trials for VP-102, aiming to provide an effective treatment for common warts, addressing significant unmet needs.

Apogee Therapeutics reveals promising phase 1b trial results for zumilokibart, highlighting its potential as a durable treatment for atopic dermatitis.

Expert consensus clarifies systemic corticosteroid use in atopic dermatitis, emphasizing risks and advocating for advanced therapies for better patient outcomes.

Explore how precision dermatology leverages immune pathways to enhance treatment for inflammatory skin diseases.

Envudeucitinib shows promising results as a new oral therapy for psoriasis, achieving high skin clearance rates and rapid symptom improvement in clinical trials.

Discover how a novel 1550 nm laser treatment effectively addresses acne scarring in diverse skin types, enhancing safety and results for all.

Explore the latest French guidelines for systemic psoriasis therapy, highlighting new treatments and tailored management strategies for diverse patient needs.

Explore the latest insights on hyperhidrosis, its impact on quality of life, and advancements in effective treatment options for this often-overlooked condition.

Explore the latest advancements in dermatology for 2026, featuring innovative therapies and treatments for skin conditions, hair loss, and more.

Explore the top headlines of 2025, including insights on the latest clinical trials, therapeutic updates, and more.

Discover groundbreaking FDA dermatology approvals in 2025, featuring innovative therapies for chronic skin conditions and pediatric care advancements.

Dermatology evolves in 2025, focusing on personalized care, safety, and technology integration, while addressing systemic health and patient outcomes.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Discover the latest advancements in psoriasis treatment, including innovative therapies and personalized care options for improved patient outcomes in 2025.

Discover the latest advancements in CSU treatment, including new therapies and evolving management strategies for better patient outcomes.

Pediatric dermatology experiences a transformative shift, enhancing care for younger patients and expanding therapeutic options.

Discover the latest advancements in hidradenitis suppurativa therapies, including promising biologics and oral treatments reshaping patient care in 2025.

Erik Domingues leads a vital discussion on innovative vitiligo management, addressing treatment challenges and psychosocial impacts in diverse patient populations.

Michael O'Donoghue, MD, shares insights on actinic keratosis management, emphasizing personalized therapy strategies.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.